Evaluation of bacteriophage therapy to control clostridium difficile and toxin production in an invitro human colon model system

Anaerobe

Volumn 22, Issue , 2013, Pages 25-30

  Meader, Emma ^a,b   Mayer, Melinda J ^a   Steverding, Dietmar ^b   Carding, Simon R ^a,b   Narbad, Arjan ^a  

^a INSTITUTE OF FOOD RESEARCH   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Bacteriophage therapy; Clostridium difficile; Human colon model; Lysogeny; Toxin

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B;

AEROBIC BACTERIUM; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIAL SPORE; BACTERIOPHAGE; BACTEROIDES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMENSAL; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; ENTEROBACTERIACEAE; IN VITRO STUDY; INFECTION CONTROL; INTESTINE FLORA; LACTOBACILLUS; LYSOGENIZATION; NONHUMAN; PRIORITY JOURNAL; TOXIN SYNTHESIS;

BACTERIOPHAGE THERAPY; CLOSTRIDIUM DIFFICILE; HUMAN COLON MODEL; LYSOGENY; TOXIN;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; BACTERIOPHAGES; BIOLOGICAL THERAPY; CELLS, CULTURED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLON; HUMANS; LYSOGENY; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE;

EID: 84880755457     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2013.05.001     Document Type: Article

References (28)

1. Mandatory surveillance of clostridium difficile 2011, HPA. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ClostridiumDifficile/EpidemiologicalData/MandatorySurveillance/.
2. Starr J.M., Martin H., McCoubrey J., Gibson G., Poxton I.R. Risk factors for Clostridium difficile colonisation and toxin production. Age Ageing 2003, 32:657-660.
3. Huang H., Nord C.E. Can metronidazole still be used for treatment of Clostridium difficile infections?. Curr Infect Dis Rep 2009, 11:3-6.
4. Jung K.S., Park J.J., Chon Y.E., Junf E.S., Lee H.J., Jang H.W., et al. Risk factors for treatment failure and recurrence after metronidazole treatment for Clostridium-difficile-associated diarrhoea. Gut Liver 2010, 4:332-337.
5. Saginur R., Hawley C.R., Bartlett J.G. Colitis associated with metronidazole therapy. JInfect Dis 1980, 141:772-774.
6. Venugopal A.A., Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012, 55(Suppl. 2):S71-S76.
7. d' Herelle F. Sur un microbe invisible antagoniste des bacilles dysenterique. Acad Sci 1917, 165:373-375.
8. Mann N.H. The potential of phages to prevent MRSA infections. Res Microbiol 2008, 159:400-405.
9. Fortier L.C., Moineau S. Morphological and genetic diversity of temperate phages in Clostridium difficile. Appl Environ Microbiol 2007, 73:7358-7366.
10. Goh S., Riley T.V., Chang B.J. Isolation and characterization of temperate bacteriophages of Clostridium difficile. Appl Environ Microbiol 2005, 71:1079-1083.
11. Govind R., Fralick J.A., Rolfe R.D. Genomic organization and molecular characterization of Clostridium difficile bacteriophage ΦCD119. JBacteriol 2006, 188:2568-2577.
12. Horgan M., O'Sullivan O., Coffey A., Fitzgerald G.F., van Sinderen D., McAuliffe O., et al. Genome analysis of the Clostridium difficile phage ΦCD6356, a temperate phage of the Siphoviridae family. Gene 2010, 462:34-43.
13. Mayer M.J., Narbad A., Gasson M.J. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. JBacteriol 2008, 190:6734-6740.
14. Mahony D.E., Bell P.D., Easterbrook K.B. Two bacteriophages of Clostridium difficile. JClin Microbiol 1985, 21:251-254.
15. Kutter E., Sulakvelidze A. Bacteriophages: biology and applications 2005, CRC Press, Boca Raton.
16. Meader E., Mayer M.J., Gasson M.J., Steverding D., Carding S.R., Narbad A. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an invitro model system. Anaerobe 2010, 16:549-554.
17. Freeman J., Baines S.D., Saxton K., Wilcox M.H. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. JAntimicrob Chemother 2007, 60:83-91.
18. Macfarlane G.T., Macfarlane S., Gibson G.R. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998, 35:180-187.
19. Oguntoyinbo F.A., Tourlomousis P., Gasson M.J., Narbad A. Analysis of bacterial communities of traditional fermented West African cereal foods using culture independent methods. Int J Food Microbiol 2011, 145:205-210.
20. Pereira C., Salvador S., Arrojado C., Silva Y., Santos A.L., Cunha A., et al. Evaluating seasonal dynamics of bacterial communities in marine fish aquaculture: a preliminary study before applying phage therapy. JEnviron Monit 2011, 13:1053-1058.
21. Baines S.D., O'Connor R., Saxton K., Freeman J., Wilcox M.H. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. JAntimicrob Chemother 2009, 63:520-525.
22. Mutters R., Nonnenmacher C., Susin C., Albrecht U., Kropatsch R., Schumacher S. Quantitative detection of Clostridium difficile in hospital environmental samples by real-time polymerase chain reaction. JHosp Infect 2009, 71:43-48.
23. Freeman J., Baines S.D., Jabes D., Wilcox M.H. Comparison of the efficacy of ramoplanin and vancomycin in both invitro and invivo models of clindamycin-induced Clostridium difficile infection. JAntimicrob Chemother 2005, 56:717-725.
24. Govind R., Fralick J.A., Rolfe R.D. Invivo lysogenization of a Clostridium difficile bacteriophage ΦCD119. Anaerobe 2011, 17:125-129.
25. Govind R., Vediyappan G., Rolfe R.D., Dupuy B., Fralick J.A. Bacteriophage-mediated toxin gene regulation in Clostridium difficile. JVirol 2009, 83:12037-12045.
26. Sekulovic O., Meessen-Pinard M., Fortier L.C. Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. JBacteriol 2011, 193:2726-2734.
27. Rea M.C., Dobson A., O'Sullivan O., Crispie F., Fouhy F., Cotter P.D., et al. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci USA 2011, 108(Suppl. 1):4639-4644.
28. Baines S.D., Freeman J., Wilcox M.H. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009, 53:2202-2204.